Trials / Unknown
UnknownNCT04822792
Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT
Pan-cancer Early-stage Detection by Liquid Biopsy in Peripheral Blood: a Multi-center, Prospective Observational Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 11,879 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- —
Summary
PRESCIENT is a multi-center, prospective observational study aimed to detect cancers early by combined assays for serum protein markers and cell-free DNA (cfDNA) methylation markers. Blood RNA markers will also be evaluated. The study will enroll approximately 11879 participants, including participants with malignancies or benign diseases, and healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Multi-cancer early detection test | Blood collection and multi-cancer early detection test |
Timeline
- Start date
- 2021-03-23
- Primary completion
- 2023-03-31
- Completion
- 2023-06-30
- First posted
- 2021-03-30
- Last updated
- 2021-06-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04822792. Inclusion in this directory is not an endorsement.